Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Plasticity of the Immune System in Children Following Treatment Interruption in HIV-1 Infection.

Tytuł:
Plasticity of the Immune System in Children Following Treatment Interruption in HIV-1 Infection.
Autorzy:
Sandgaard KS; Great Ormond Street Institute of Child Health, University College London, London, United Kingdom.; Department of Pediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark.
Margetts B; Molecular Haematology, Great Ormond Street Hospital for Children, London, United Kingdom.
Attenborough T; Great Ormond Street Institute of Child Health, University College London, London, United Kingdom.; UCL Centre for Computation, Mathematics, and Physics in the Life Sciences and Experimental Biology (CoMPLEX), London, United Kingdom.
Gkouleli T; Great Ormond Street Institute of Child Health, University College London, London, United Kingdom.
Adams S; Molecular Haematology, Great Ormond Street Hospital for Children, London, United Kingdom.
Holm M; Department of Pediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark.
Gibb D; Medical Research Council Clinical Trials Unit, London, United Kingdom.
Gibbons D; Peter Gorer Department of Immunobiology, Kings College London, London, United Kingdom.
Giaquinto C; Department of Mother and Child Health, University of Padova, Padova, Italy.
De Rossi A; Section of Oncology and Immunology, Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.; Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV - IRCCS, Padova, Italy.
Bamford A; Great Ormond Street Institute of Child Health, University College London, London, United Kingdom.; Molecular Haematology, Great Ormond Street Hospital for Children, London, United Kingdom.; Medical Research Council Clinical Trials Unit, London, United Kingdom.
Palma P; Clinical and Research Unit of Clinical Immunology and Vaccinology, Academic Department of Pediatrics, Children Hospital Bambino Gesù - IRCCS, Rome, Italy.
Chain B; Division of Infection and Immunity, University College London, London, United Kingdom.
Gkazi AS; Zayed Centre for Research into Rare Disease in Children, University College London, London, United Kingdom.
Klein N; Great Ormond Street Institute of Child Health, University College London, London, United Kingdom.
Źródło:
Frontiers in immunology [Front Immunol] 2021 Jul 29; Vol. 12, pp. 643189. Date of Electronic Publication: 2021 Jul 29 (Print Publication: 2021).
Typ publikacji:
Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Język:
English
Imprint Name(s):
Original Publication: [Lausanne : Frontiers Research Foundation]
MeSH Terms:
Antiretroviral Therapy, Highly Active*
Anti-HIV Agents/*therapeutic use
HIV Infections/*drug therapy
HIV-1/*drug effects
Immune System/*drug effects
Adolescent ; CD4 Lymphocyte Count ; CD4-Positive T-Lymphocytes/drug effects ; CD4-Positive T-Lymphocytes/immunology ; CD4-Positive T-Lymphocytes/virology ; CD8-Positive T-Lymphocytes/drug effects ; CD8-Positive T-Lymphocytes/immunology ; CD8-Positive T-Lymphocytes/virology ; Child ; Child, Preschool ; Follow-Up Studies ; HIV Infections/immunology ; HIV Infections/virology ; HIV-1/immunology ; HIV-1/physiology ; Humans ; Immune System/cytology ; Immune System/immunology ; Receptors, Antigen, T-Cell/immunology ; Receptors, Antigen, T-Cell/metabolism ; Viral Load/drug effects ; Viral Load/immunology
References:
PLoS Med. 2013 Oct;10(10):e1001542. (PMID: 24204216)
J Immunol. 2001 Dec 1;167(11):6663-8. (PMID: 11714838)
Methods Mol Biol. 2019;1884:15-42. (PMID: 30465193)
AIDS. 2013 Feb 20;27(4):579-89. (PMID: 23135172)
Bioinformatics. 2013 Mar 1;29(5):542-50. (PMID: 23303508)
Nat Immunol. 2012 Jun 10;13(7):691-700. (PMID: 22683743)
Nat Med. 2019 Oct;25(10):1549-1559. (PMID: 31591606)
PLoS One. 2018 Apr 23;13(4):e0196239. (PMID: 29684092)
PLoS One. 2013 Sep 02;8(9):e73849. (PMID: 24023909)
Eur J Haematol. 2008 Jun;80(6):532-9. (PMID: 18284628)
AIDS. 2010 Jan 16;24(2):231-41. (PMID: 20010073)
AIDS. 2014 Jan 14;28(2):209-14. (PMID: 24072195)
Blood. 2009 May 28;113(22):5480-7. (PMID: 19179300)
Curr Opin Immunol. 2005 Oct;17(5):468-75. (PMID: 16098723)
Nat Commun. 2020 Aug 14;11(1):4089. (PMID: 32796830)
J Immunol. 2009 Oct 1;183(7):4329-36. (PMID: 19734223)
Clin Exp Immunol. 2018 Feb;191(2):198-202. (PMID: 28976005)
Nat Med. 2017 Jan 6;23(1):18-27. (PMID: 28060797)
Nature. 2017 Jul 6;547(7661):94-98. (PMID: 28636589)
Eur J Pediatr. 1977 Aug 12;125(4):227-34. (PMID: 891567)
HIV Med. 2021 Mar;22(3):172-184. (PMID: 33124144)
Front Immunol. 2017 Oct 12;8:1267. (PMID: 29075258)
Immun Ageing. 2008 Jul 25;5:6. (PMID: 18657274)
N Engl J Med. 2006 Nov 30;355(22):2283-96. (PMID: 17135583)
Blood. 2011 Aug 25;118(8):2138-49. (PMID: 21734237)
Nat Med. 2014 Oct;20(10):1206-10. (PMID: 25242415)
J Immunol. 2005 Jun 1;174(11):7446-52. (PMID: 15905594)
AIDS. 2001 Sep 28;15(14):1757-64. (PMID: 11579236)
J Immunol. 2017 Sep 1;199(5):1696-1705. (PMID: 28754679)
Nature. 2017 Jul 6;547(7661):89-93. (PMID: 28636592)
Brief Bioinform. 2018 Jul 20;19(4):554-565. (PMID: 28077404)
PLoS One. 2013 Oct 23;8(10):e76582. (PMID: 24194841)
Front Immunol. 2018 Nov 05;9:2547. (PMID: 30455696)
Grant Information:
MC_UU_00004/03 United Kingdom MRC_ Medical Research Council
Contributed Indexing:
Keywords: HIV-1; T cell receptor; T cells; T cell receptor clonal expansions; antiretroviral treatment interruption; high throughout sequencing; immune repertoires; thymic output
Substance Nomenclature:
0 (Anti-HIV Agents)
0 (Receptors, Antigen, T-Cell)
Entry Date(s):
Date Created: 20210903 Date Completed: 20210927 Latest Revision: 20231115
Update Code:
20240105
PubMed Central ID:
PMC8406805
DOI:
10.3389/fimmu.2021.643189
PMID:
34475868
Czasopismo naukowe
It is intriguing that, unlike adults with HIV-1, children with HIV-1 reach a greater CD4 + T cell recovery following planned treatment cessation. The reasons for the better outcomes in children remain unknown but may be related to increased thymic output and diversity of T cell receptor repertoires. HIV-1 infected children from the PENTA 11 trial tolerated planned treatment interruption without adverse long-term clinical, virological, or immunological consequences, once antiretroviral therapy was re-introduced. This contrasts to treatment interruption trials of HIV-1 infected adults, who had rapid changes in T cells and slow recovery when antiretroviral therapy was restarted. How children can develop such effective immune responses to planned treatment interruption may be critical for future studies. PENTA 11 was a randomized, phase II trial of planned treatment interruptions in HIV-1-infected children (ISRCTN 36694210). In this sub-study, eight patients in long-term follow-up were chosen with CD4 + count>500/ml, viral load <50c/ml at baseline: four patients on treatment interruption and four on continuous treatment. Together with measurements of thymic output, we used high-throughput next generation sequencing and bioinformatics to systematically organize memory CD8 + and naïve CD4 + T cell receptors according to diversity, clonal expansions, sequence sharing, antigen specificity, and T cell receptor similarities following treatment interruption compared to continuous treatment. We observed an increase in thymic output following treatment interruption compared to continuous treatment. This was accompanied by an increase in T cell receptor clonal expansions, increased T cell receptor sharing, and higher sequence similarities between patients, suggesting a more focused T cell receptor repertoire. The low numbers of patients included is a limitation and the data should be interpreted with caution. Nonetheless, the high levels of thymic output and the high diversity of the T cell receptor repertoire in children may be sufficient to reconstitute the T cell immune repertoire and reverse the impact of interruption of antiretroviral therapy. Importantly, the effective T cell receptor repertoires following treatment interruption may inform novel therapeutic strategies in children infected with HIV-1.
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
(Copyright © 2021 Sandgaard, Margetts, Attenborough, Gkouleli, Adams, Holm, Gibb, Gibbons, Giaquinto, De Rossi, Bamford, Palma, Chain, Gkazi and Klein.)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies